amonafide has been researched along with Ovarian Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberts, DS; Dorr, RT; Remers, WA; Sami, SM | 1 |
| Asbury, RF; Blessing, JA; Clarke-Pearson, D; Homesley, HD; Look, KY | 1 |
| Alberts, DE; Gallion, HH; Hynes, HE; Liu, PY; Mills, G; O'Sullivan, J; O'Toole, RV; Smith, HO | 1 |
2 trial(s) available for amonafide and Ovarian Neoplasms
| Article | Year |
|---|---|
A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Organophosphonates; Ovarian Neoplasms | 1993 |
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
Topics: Adenine; Adult; Aged; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Middle Aged; Naphthalimides; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organophosphonates; Ovarian Neoplasms | 1992 |
1 other study(ies) available for amonafide and Ovarian Neoplasms
| Article | Year |
|---|---|
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
Topics: Animals; Antineoplastic Agents; Female; Humans; Isoquinolines; Leukemia L1210; Leukemia P388; Male; Melanoma, Experimental; Mice; Mice, Inbred DBA; Ovarian Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |